Drug Profile


Alternative Names: Dironyl; Dironyl maleate; Mysalfon; SH 406; Teluron; Transdihydrolisuride; VUFB 6638; ZK 31224

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer Schering Pharma; Bayer Yakuhin; ErgoNex Pharma; IVAX Pharmaceuticals s.r.o.; Pfizer
  • Class Antiparkinsonians; Antipsychotics; Ergolines; Neuroprotectants; Small molecules; Urea compounds
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperprolactinaemia
  • Discontinued Fibromyalgia; Fibrosis; Parkinson's disease; Pulmonary arterial hypertension; Schizophrenia

Most Recent Events

  • 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Germany (unspecified route)
  • 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Netherlands (unspecified route)
  • 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top